Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / COM
-
Number of holders
-
12
-
Total 13F shares, excl. options
-
1,006,151
-
Shares change
-
+1,006,151
-
Total reported value, excl. options
-
$15,020,000
-
Value change
-
+$15,020,002
-
Number of buys
-
12
-
Price
-
$14.92
Significant Holders of Gain Therapeutics, Inc. - COM (GANX) as of Q1 2021
12 filings reported holding GANX - Gain Therapeutics, Inc. - COM as of Q1 2021.
Gain Therapeutics, Inc. - COM (GANX) has 12 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1,006,151 shares
.
Largest 10 shareholders include GREENLIGHT CAPITAL INC (546,560 shares), Granite Point Capital Management, L.P. (225,000 shares), AIGH Capital Management LLC (65,809 shares), PRELUDE CAPITAL MANAGEMENT, LLC (58,100 shares), JANE STREET GROUP, LLC (22,754 shares), Maven Securities LTD (22,124 shares), Worth Venture Partners, LLC (15,532 shares), Davidson Kempner Capital Management LP (15,000 shares), MILLENNIUM MANAGEMENT LLC (14,367 shares), and MYDA Advisors LLC (14,000 shares).
This table shows the top 12 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.